CSL Behring Fact Sheet
- Download Canada Fact Sheet
CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufacturers and markets a range of plasma-derived and recombinant therapies worldwide.
CSL Behring therapies are indicated for the treatment of coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, inherited respiratory disease and hereditary angiodema. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in newborns.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited, a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.
Dr. Ingolf Sieper
Exec. Vice President,
Exec VP, Plasma, Supply Chain and Information Systems
|Employees ||9,000+ employees in 19 countries|
|Headquarters ||King of Prussia, Pennsylvania, USA|
|Plasma Collection||CSL Plasma is one of the world’s largest plasma collection organizations. The company operates collection centers across the United States and Germany. Headquarters are in Boca Raton, Florida. Testing laboratoriesare located in the Unites States and Germany.|
|Manufacturing||Bern, Switzerland: center of excellence for immunoglobulins; Marburg, Germany: center of excellence for coagulation products; and Kankakee, Illinois, USA: center of excellence for Alpha1 proteinase inhibitor.|
|R&D||CSL integrated R&D includes facilities in Marburg, Germany; Bern, Switzerland; King of Prussia, Pennsylvania, USA; Kankakee, Illinois, USA; Tokyo, Japan; and Broadmeadows and Parkville, Australia|
|2008/09 Sales||Approximately U.S. $2.98 billion|
Return to Top
|Coagulation||Therapies to treat bleeding disorders including hemophilia and von Willebrand disease|
|Immune Deficiencies ||Products used to treat immunological disorders, such as primary immune deficiency, Idiopathic Thrombocytopenic Purpura (ITP), Guillain-Barré Syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP) and hemolytic disease of the newborn|
|Pulmonary||Therapies used to treat Alpha1-Antitrypsin Deficiency (genetic condition resulting in liver and lung failure)|
|Critical Care||Critical care products for Hereditary Angioedema, treatment of shock and burns, and fluid replacement therapy|
|Wound Healing||Therapies used in surgery and the treatment of wounds to facilitate healing|
Return to Top